- Home
- CRGX vs PLMK Comparison
CRGX vs PLMK Comparison
Compare CRGX & PLMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- PLMK
- Stock Information
- Founded
- CRGX 2021
- PLMK 2024
- Country
- CRGX United States
- PLMK United States
- Employees
- CRGX N/A
- PLMK N/A
- Industry
- CRGX
- PLMK
- Sector
- CRGX
- PLMK
- Exchange
- CRGX Nasdaq
- PLMK NYSE
- Market Cap
- CRGX 213.5M
- PLMK 241.7M
- IPO Year
- CRGX 2023
- PLMK 2025
- Fundamental
- Price
- CRGX $4.02
- PLMK $10.13
- Analyst Decision
- CRGX Hold
- PLMK
- Analyst Count
- CRGX 7
- PLMK 0
- Target Price
- CRGX $4.67
- PLMK N/A
- AVG Volume (30 Days)
- CRGX 763.5K
- PLMK 231.1K
- Earning Date
- CRGX 05-16-2025
- PLMK 01-01-0001
- Dividend Yield
- CRGX N/A
- PLMK N/A
- EPS Growth
- CRGX N/A
- PLMK N/A
- EPS
- CRGX N/A
- PLMK N/A
- Revenue
- CRGX N/A
- PLMK N/A
- Revenue This Year
- CRGX $58.18
- PLMK N/A
- Revenue Next Year
- CRGX N/A
- PLMK N/A
- P/E Ratio
- CRGX N/A
- PLMK N/A
- Revenue Growth
- CRGX N/A
- PLMK N/A
- 52 Week Low
- CRGX $3.00
- PLMK $9.94
- 52 Week High
- CRGX $25.45
- PLMK $10.19
- Technical
- Relative Strength Index (RSI)
- CRGX 37.02
- PLMK N/A
- Support Level
- CRGX $3.97
- PLMK N/A
- Resistance Level
- CRGX $4.66
- PLMK N/A
- Average True Range (ATR)
- CRGX 0.20
- PLMK 0.00
- MACD
- CRGX -0.05
- PLMK 0.00
- Stochastic Oscillator
- CRGX 6.25
- PLMK 0.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About PLMK PLUM ACQUISITION CORP IV
Plum Acquisition Corp IV is a blank check company.